Interim report January-March 2015
Unless otherwise stated in this report, all data refers to the Group. Figures in parentheses relate to the corresponding period in 2014. First quarter shows continued sales growth and positive cash flow. Broadening of Zubsolv® dosage range proceeds. First quarter 2015 · Total net revenues amounted to MSEK 149.0 (101.9). · Earnings after tax were MSEK -15.5 (-21.1). · Earnings per share were SEK -0.45 (-0.66). · Cash flow from operating activities was positive and amounted to MSEK 6.5 (-99.7). · Cash and cash equivalents amounted to MSEK 289.3 (30.7). · Orexo